ACHE and Alzheimer disease: Rivastigmine, galantamine and Donepezil are FDA-approved drugs based on the “one drug–one target” approach that were currently used to treat Alzheimer candidates by blocking AChE, underlining the shortcomings of this approach for the complex nature of AD.